ERBB2 and granular cell tumor: GCTs respond to the targeting of EGF receptors HER3-4 with a cytotoxic ligand in vitro 17, and the results of this study imply that HER2 is also a potential target in the development of new treatment strategies for GCT patients, especially for patients with high-risk HER2-expressing tumors.